Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00894712|
Recruitment Status : Unknown
Verified October 2014 by Sidney Kimmel Comprehensive Cancer Center.
Recruitment status was: Active, not recruiting
First Posted : May 7, 2009
Last Update Posted : October 3, 2014
The investigators plan to investigate the protective effects of topical sulforaphane-containing broccoli-sprout extracts (BSE) on radiation-induced dermatitis in women undergoing external-beam radiation therapy for breast cancer. Topical sulforaphane induces phase 2 enzymes that are protective against oxidants, electrophiles, and inflammation (Talalay and Fahey, 2001) - all of which are generated by both ultraviolet and ionizing radiation. Previous work from the investigators' group demonstrated that sulforaphane treatment protects against ultraviolet radiation-induced erythema of human skin (IRB protocol NA_00004897; Talalay et al. 2007). This investigation will extend the investigators' previous work by employing ionizing rather than ultraviolet radiation.
The investigators propose a two part sequential protocol (Study A and Study B). Both studies will involve women with breast cancer who have undergone lumpectomy and are scheduled for adjuvant external beam radiation treatment. In study A, the investigators will validate their technique for measurement of skin erythema using a device called a chromometer; no active agent will be applied (up to 6 women). Study B will follow completion of Study A. Study B will involve the application of broccoli sprout extracts (BSE) or vehicle alone to determine if sulforaphane can reduce radiation-induced erythema (27 women). Four adjacent, 1.5-cm diameter areas-of-interest on the affected breast will be located by means of an adhesive vinyl template which can be accurately and repeatedly placed at the same position. Two of the four areas will be treated with BSE (active agent) and two with vehicle (inactive control). BSE will be applied on three days weekly throughout the 5-week period of whole breast radiation. Erythema will be noninvasively quantified by measuring the red-reflectance of the skin with a chromometer up to three times weekly throughout treatment. A total of 33 patients are to be enrolled.
The investigators' objective is to determine and quantify the effect of topical BSE on radiation-induced skin erythema. This study will employ standard, clinically-accepted radiation doses and techniques that are safe and well tolerated. The safety and tolerability of both oral and topical broccoli sprout preparations is well established; no safety concerns have been noted. (Shapiro et al. 2006; Dinkova-Kostova et al. 2007).
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Dermatitis||Other: Sulforaphane-containing broccoli sprout extracts (active agent) Device: Vehicle (inactive control)||Phase 2|
|Study Type :||Observational|
|Estimated Enrollment :||32 participants|
|Official Title:||Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer|
|Study Start Date :||April 2009|
|Primary Completion Date :||November 2012|
|Estimated Study Completion Date :||November 2015|
Other: Sulforaphane-containing broccoli sprout extracts (active agent)
- Variance of the skin erythema measurements due to non-radiation effects. [ Time Frame: Week 0 and Week 1 of radiation treatment ]
- Absolute change in red reflectance of the skin. [ Time Frame: before and after radiation ]
- Clinical grade of dermatitis (per NCI CTCAE v3.0 guidelines) for each region. [ Time Frame: weekly ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00894712
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21231|
|Principal Investigator:||Richard Zellars, M.D.||Johns Hopkins University|